Today, not all women diagnosed with early-stage breast cancer needs chemotherapy. In fact, up to 3 out of 4 patients with early-stage, hormone receptor-positive breast cancer may not benefit from chemotherapy. This calls for a personalized cancer treatment where every patient’s tumor is deeply studied for a better clinical outcome.

CanAssist Breast is a prognostic test that offers insights about tumor biology, thereby, helping oncologists to determine the right treatment regimen for each patient. The CanAssist Breast risk score determines the patient’s risk of breast cancer recurrence over five years, allowing patients who are classified as ‘low-risk’ for breast cancer recurrence to avoid chemotherapy and its side-effects.

CanAssist Breast aids your doctor in personalizing your cancer treatment plan.